Meropenem Bausch Health (Meropenem Anhydrous)

Meropenem inhibits bacterial cell wall synthesis by binding to penicillin‑binding proteins (PBPs). This blocks the cross‑linking of peptidoglycan strands, weakening the cell wall and causing bacterial lysis. Its structure also resists most β‑lactamases, extending activity against many resistant organisms.

The specific dose of meropenem is determined by the prescribing clinician based on the infection type, severity, patient weight, renal function, and local susceptibility patterns. Dosing regimens are individualized and should follow the prescriber’s instructions and institutional guidelines.

Safety data for meropenem in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any potential risk to the fetus or infant. Clinicians must evaluate each case individually and discuss possible risks with the patient.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Meropenem shares a similar spectrum with other carbapenems such as imipenem‑cilastatin and ertapenem, but it offers a broader Gram‑negative coverage and is less affected by certain β‑lactamases. Choice among carbapenems depends on infection site, pathogen susceptibility, patient renal function, and safety profile.

Meropenem injectable solution should be stored at 2‑8 °C (refrigerated). Keep the product in its original packaging, protect it from light, and avoid freezing or shaking the vial. Do not use if the solution appears discolored or contains particles.

Meropenem is given as an intravenous infusion, typically over 15‑30 minutes. The infusion rate and duration are determined by the prescriber based on the dose, patient tolerance, and clinical setting. Administration should follow aseptic technique and institutional infusion protocols.

Serious risks include seizures, especially in patients with renal impairment or pre‑existing CNS disorders, Clostridioides difficile‑associated colitis, severe hypersensitivity reactions such as anaphylaxis, and profound neutropenia. Prompt recognition and management of these events are essential.

Meropenem is contraindicated in patients with a known hypersensitivity to meropenem, other carbapenems, or any β‑lactam antibiotics. Caution is also advised for individuals with a history of seizures, severe renal impairment without dose adjustment, or those receiving interacting medications that may increase toxicity.